lululemon Expands International Presence with First Store Opening in Italy
The Milan store's full concept will span approximately 5,700 square feet across two floors, offering a thoughtfully curated environment for guests with distinct spaces dedicated to lululemon's signature technical innovations. The two floors will showcase the brand's men's and women's collections – all designed through the lens of high-performance, high-style to support a wide range of activities including yoga, running, training, tennis, and golf.
Paying homage to Italy's rich design heritage, the store is expected to feature a locally inspired architectural concept that blends traditional craftsmanship with contemporary materials. A standout feature of the new store is anticipated to be the lululemon Glide sculptural façade – a striking visual expression of movement and form. The custom 3-D printed installation is set to draw inspiration from lululemon's iconic Define Jacket pattern, and its flowing geometry is designed to expand and move across the storefront, emulating the properties of fabric on an architectural scale.
In line with lululemon's omni-channel vision, the Milan store aims to offer a fully integrated guest experience. Guests can enjoy seamless access to the brand's full range via the Endless Aisle BBR (Back Back Room) solution, which is designed to help ensure availability of product beyond what is stocked in-store.
International visitors will benefit from Global Blue Tax-Free Shopping, further enhancing the guest experience in one of Europe's most popular tourist destinations.
Strategic Growth Across EMEA
The Milan store opening marks a significant step in lululemon's international expansion. The brand already operates stores in key markets including the UK, Ireland, Germany, France, Spain, the Netherlands, Norway, Sweden, and Switzerland. Entering Italy is part of lululemon's broader Power of Three ×2 growth plan, which aims to quadruple international revenue from 2021 levels by year-end 2026.
Building Community
lululemon is grounded in product innovation, guest experience, and a deep commitment to building meaningful connections. In Milan, the brand expects to engage with the local community through a series of activations planned throughout the year, which may include partnerships with local studios, run clubs, and a new ambassador program. These initiatives are intended to reflect lululemon's holistic approach to wellbeing – supporting the physical, mental, and social health of the community it serves.
About lululemon
lululemon (NASDAQ:LULU) is a technical athletic apparel, footwear, and accessories company for yoga, running, training, tennis, golf, and other activities. It creates transformational products and experiences that build meaningful connections, unlocking greater possibility and wellbeing for all. Setting the bar in innovation of fabrics and functional designs, lululemon works with athletes in local communities around the world for continuous research and product feedback. For more information about lululemon's Milan opening and latest product collections, visit eu.lululemon.com or follow @lululemoneurope on social media.
Forward-looking statements:
This press release contains forward-looking statements, which reflect lululemon's current expectations and plans. These statements are subject to various risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Factors that could affect our future performance are included in our filings with the Securities and Exchange Commission, including our most recent reports on Forms 10-K, 10-Q, and 8-K. We undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of this release.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
DOW Gears Up for Q2 Earnings: What's in the Cards for the Stock?
Dow Inc. DOW is scheduled to come up with second-quarter 2025 results before the opening bell on July 24. DOW surpassed the Zacks Consensus Estimate in two of the trailing four quarters and missed twice. It has a trailing four-quarter earnings surprise of 24.2% on average. Dow posted an earnings surprise of 200% in the last reported quarter. While DOW is expected to have benefited from its productivity initiatives, soft demand due to weak global economic activities and pricing pressures are likely to have affected its second-quarter performance. Dow's shares are down 44.4% over a year compared with the Zacks Chemicals Diversified industry's 18.4% decline. Let's see how things are shaping up for this announcement. What Do DOW's Revenue Estimates Say? The Zacks Consensus Estimate for revenues for DOW for the to-be-reported quarter is pinned at $10,445.6 million, suggesting a year-over-year decline of 4.6%. Our estimate for revenues for the Packaging & Specialty Plastics segment is currently pegged at $5,197.9 million, calling for a decline of 5.8% year over year. The same for the Industrial Intermediates & Infrastructure segment stands at $2,884.6 million, indicating a 2.3% year-over-year decline. Our estimate for revenues for the Performance Materials & Coatings segment is pinned at $2,142.1 million, suggesting a fall of 4.5% year over year. Factors Shaping DOW's Q2 Results Dow is expected to have faced headwinds from demand softness in Europe and China in the quarter to be reported. Lower consumer spending amid inflationary pressures is affecting demand in Europe. Construction and manufacturing activities remain soft in the region. Demand in Asia has been affected by a weaker demand recovery in China. The property sector in China remains sluggish, with declining new home prices. Inflationary pressures are impacting consumer durables and building and construction demand. Demand in infrastructure, including residential construction, also remains weak. Dow sees softness in automotive in Europe due to low demand. Soft conditions across these markets are likely to have weighed on DOW's volumes in the second quarter. Weak macroeconomic conditions due to disruptions caused by tariffs are expected to have affected business and consumer sentiment. Dow is also being challenged by weak siloxane prices in its Performance Materials & Coatings unit. The segment continues to see siloxane pricing pressure partly due to supply additions in Asia. Siloxane prices remain under pressure due to competitive pricing pressure resulting from additional supply driven by capacity additions in China. While capacity additions have slowed, elevated industry supply is expected to continue to have impacted prices in the second quarter. Nevertheless, Dow is likely to have benefited from cost-saving and productivity actions. DOW is implementing targeted actions focused on reducing direct costs and labor costs. It is taking action to cut costs by $1 billion to drive margins. Dow sees around $300 million in benefits from these actions in 2025, with full benefits expected by 2026. The benefits of DOW's cost-saving actions are likely to be reflected in its bottom line in the to-be-reported quarter. Dow Inc. Price and EPS Surprise Dow Inc. price-eps-surprise | Dow Inc. Quote What Our Model Unveils for DOW Stock Our proven model does not conclusively predict an earnings beat for DOW this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. But that's not the case here. Earnings ESP: Earnings ESP for DOW is -53.04%. The Zacks Consensus Estimate for the second quarter is currently pegged at a loss of 8 cents. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. Zacks Rank: DOW currently carries a Zacks Rank #5 (Strong Sell). Basic Materials Stocks That Warrant a Look Here are some companies in the basic materials space you may want to consider as our model shows they have the right combination of elements to post an earnings beat this quarter: Agnico Eagle Mines Limited AEM, scheduled to release earnings on July 30, has an Earnings ESP of +8.77% and carries a Zacks Rank #1. You can see the complete list of today's Zacks #1 Rank stocks here. The consensus estimate for AEM's earnings for the second quarter is currently pegged at $1.66. Newmont Corporation NEM, slated to release earnings on July 24, has an Earnings ESP of +4.42% and carries a Zacks Rank #2 at present. The consensus mark for NEM's second-quarter earnings is currently pegged at $1.05. Kinross Gold Corporation KGC, scheduled to release earnings on July 30, has an Earnings ESP of +15.34%. The Zacks Consensus Estimate for KGC's earnings for the second quarter is currently pegged at 27 cents. KGC currently carries a Zacks Rank #1. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Dow Inc. (DOW): Free Stock Analysis Report Newmont Corporation (NEM): Free Stock Analysis Report Kinross Gold Corporation (KGC): Free Stock Analysis Report Agnico Eagle Mines Limited (AEM): Free Stock Analysis Report
Globe and Mail
an hour ago
- Globe and Mail
Lantern Pharma (NASDAQ: LTRN) Secures EU Patent for AI-Designed Cancer Drug LP-284
Lantern Pharma (NASDAQ: LTRN) announced the European Patent Office has issued a notice of allowance for a composition of matter patent covering LP-284, a clinical-stage drug candidate for relapsed or refractory non-Hodgkin's lymphoma. The patent, expected to grant with exclusivity through 2039, adds to existing IP in the U.S. and Japan and supports global commercialization efforts. LP-284, developed using Lantern's RADR(R) AI platform, is in Phase 1 trials and holds Orphan Drug Designations for MCL and HGBL. The drug targets a $4 billion global market, and its rapid development timeline and cost efficiency bolster Lantern's strategic partnership potential. To view the full press release, visit About Lantern Pharma Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. The company's proprietary AI and machine learning platform, RADR(R), leverages over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, Lantern has accelerated the development of its growing pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers. On average, Lantern's newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $2.5 million per program. NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company's newsroom at About BioMedWire BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today's market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text 'Biotech' to 888-902-4192 (U.S. Mobile Phones Only) For more information please visit Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:
National Post
2 hours ago
- National Post
Cizzle Brands Launches Rocket Berry Blast, a New Flavour of CWENCH Hydration™, in Collaboration with Montreal Canadiens Star Forward Cole Caufield
Article content As demand for original and newly introduced flavours of CWENCH Hydration™ continues to surge, Cizzle Brands has partnered with Cole Caufield to launch Rocket Berry Blast, marking the brand's newest limited-time flavour. CWENCH Hydration™ is now available in over 3,300 points of distribution across North America and Europe. Article content TORONTO — Cizzle Brands Corporation (Cboe Canada: CZZL) (OTCQB: CZZLF) (Frankfurt: 8YF) (the 'Company' or 'Cizzle Brands'), is pleased to announce today's official debut of Rocket Berry Blast, a new flavour of Cizzle Brands' flagship sports drink, CWENCH Hydration™, which offers a sweet and juicy taste profile that is perfect for the summer season. Article content Article content Cizzle Brands teamed up with Montreal Canadien star right winger, Cole Caufield, to develop Rocket Berry Blast and make it available to athletes of all ages across North America. Article content The launch of Rocket Berry Blast builds on the sustained growth of CWENCH Hydration™ across North America following the product's initial launch in late May of 2024. In addition to Rocket Berry Blast and its initial four core flavours (Rainbow Swirl, Blue Raspberry, Berry Crush and Cherry Lime), Cizzle Brands has successfully introduced three new limited-run flavours, including Tropical Flow and Pink Lemon Flow made in collaboration with Coach Chippy, as well as Celly Freeze launched in collaboration with Chippy, Austen Alexander, Coach Jeremy, Nasher, Pavel Barber and Swaggy P (Pete Lenes). The success of Tropical Flow has been so marked that Cizzle Brands has now added it as one of its core flavours. Article content At the time of this launch, the Rocket Berry Blast flavour of CWENCH Hydration™ is being sold by the following retailers: Article content FGL: Entrepot du Hockey; Sports Rousseau; Hockey Experts; ShopSante; and Source for Sports. Article content Cizzle Brands' Founder, Chairman, and Chief Executive Officer John Celenza commented, 'It seems that athletes of all ages just can't get enough of CWENCH Hydration™, which becomes even more evident whenever we launch a new flavour. The success of Tropical Flow, Pink Lemon Flow and Celly Freeze have all blown past our already high expectations, and we expect Rocket Berry Blast to do the same. It's one of our favourite flavours to date, perfect for being active during the summer or for long days at the rink. We couldn't have picked a better teammate than Cole Caufield to bring it to life. He is a true star in all respects and is loved in Quebec, where we're seeing strong growth and want to build an even stronger presence for CWENCH and all our products.' Article content About Cizzle Brands Corporation Article content Cizzle Brands Corporation is a sports nutrition company that is elevating the game in health and wellness. Through extensive collaboration and testing with leading athletes and trainers across several elite sports, Cizzle Brands has launched two leading product lines in the sports nutrition category: (i) CWENCH Hydration™, a better-for-you sports drink that is now carried in over 3,300 locations in Canada, the United States, and Europe; and (ii) Spoken Nutrition, a premium brand of athlete-grade nutraceuticals that carry the prestigious NSF Certified for Sport® qualification. All Cizzle Brands products are designed to help people achieve their best in both competitive sports and in living a healthy, vibrant, active lifestyle. Article content This news release contains 'forward-looking information' which may include, but is not limited to, information with respect to the activities, events or developments that the Company expects or anticipates will or may occur in the future, such as, but not limited to: new products of the Company and potential sales and distribution opportunities. Such forward-looking information is often, but not always, identified by the use of words and phrases such as 'plans', 'expects', 'is expected', 'budget', 'scheduled', 'estimates', 'forecasts', 'intends', 'anticipates', or 'believes' or variations (including negative variations) of such words and phrases, or state that certain actions, events or results 'may', 'could', 'would', 'might' or 'will' be taken, occur or be achieved. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the Company. Article content Forward looking information involves known and unknown risks, uncertainties and other risk factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such risks include risks related to increased competition and current global financial conditions, access and supply risks, reliance on key personnel, operational risks, regulatory risks, financing, capitalization and liquidity risks. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company undertakes no obligation, except as otherwise required by law, to update these forward-looking statements if management's beliefs, estimates or opinions, or other factors change. Article content Article content Article content Article content Contacts Article content Article content
